Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245678 | 0.84 | HTT (0.50) | ALDH1A1SMN1; SMN2TDP1HTTLMNA | |
| SCHEMBL7805532 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TDP1POLBHTT | |
| SCHEMBL854197 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TDP1POLBHTT | |
| SCHEMBL5635329 | 0.84 | HTT (0.50) | ALDH1A1SMN1; SMN2TDP1HTTLMNA | |
| SCHEMBL27584960 | 0.83 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TDP1HTTLMNA | |
| SCHEMBL4879328 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2TDP1HTTLMNA | |
| SCHEMBL31177578 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2TDP1POLBAPEX1 | |
| SCHEMBL2074082 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TDP1HTTLMNA | |
| SCHEMBL2074086 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TDP1HTTLMNA | |
| SCHEMBL839543 | 0.78 | GAA (0.67) | ALDH1A1SMN1; SMN2TDP1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288376-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8143248-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-1987010-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2010-04-07 | — | — | EP | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| EP-1987010-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007088277-A1 | TRICYCLIC Ν-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, CYP3A43 | ALDH1A1 453/4885SMN1; SMN2 3560/4885TDP1 2723/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | ALDH1A1 484/4885SMN1; SMN2 3750/4885TDP1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.